Literature DB >> 7900834

X-linked hypophosphatemic rickets and the murine Hyp homologue.

K A Hruska1, L Rifas, S L Cheng, A Gupta, L Halstead, L Avioli.   

Abstract

Recent studies have reported the cloning of several sodium-dependent phosphate cotransport proteins from the apical membrane of proximal tubules of several species. The human proximal tubule apical sodium-phosphate cotransport protein maps to chromosome 5 in the 5q35 region, indicating that this gene is not a candidate for the genetic defect leading to X-linked hypophosphatemia (XLH). Studies in what is thought to be the murine XLH homologue, Hyp, also indicate that the proximal tubular phosphate cotransporter gene does not map to the X chromosome. In Hyp, message levels for the apical membrane sodium cotransport protein are reduced by approximately 50%, similar to the reductions in the apical membrane protein levels of the transporter. This indicates a potential transcriptional defect in Hyp, leading to underexpression of the sodium-dependent phosphate transport protein. Recent studies in the Hyp osteoblast have characterized the intrinsic abnormalities of the cell leading to the osteomalacia characteristic of both Hyp and XLH. These studies demonstrate that the Hyp osteoblast expresses normal rates of phosphate transport, but altered gluconeogenesis similar to the proximal tubule, and that there is an underphosphorylation of an important matrix protein, osteopontin. Since osteopontin is involved in matrix mineralization, defective posttranslational modification of the protein could be a factor in producing the osteomalacia of the Hyp. Other recent studies have demonstrated improved modalities of treatment for Hyp and potentially for XLH. These involve the use of phosphate and nonhypercalcemic analogues of 1 alpha,25-dihydroxyvitamin D3. Thus, although the detection of the genetic defect producing XLH and Hyp is awaited, significant advances in the characterization of the phenotype and the bone abnormalities continue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7900834     DOI: 10.1152/ajprenal.1995.268.3.F357

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

Review 1.  FGF23 and Phosphate Wasting Disorders.

Authors:  Xianglan Huang; Yan Jiang; Weibo Xia
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

2.  Effect of Cholecalciferol therapy on serum FGF23 in vitamin D deficient patients: a randomized clinical trial.

Authors:  T Kamelian; F Saki; M Jeddi; M H Dabbaghmanesh; G H R Omrani
Journal:  J Endocrinol Invest       Date:  2017-08-09       Impact factor: 4.256

3.  Correction of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatin.

Authors:  Peter S N Rowe; Naoko Matsumoto; Oak D Jo; Remi N J Shih; Jeannine Oconnor; Martine P Roudier; Steve Bain; Shiguang Liu; Jody Harrison; Norimoto Yanagawa
Journal:  Bone       Date:  2006-06-09       Impact factor: 4.398

Review 4.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.

Authors:  Peter S N Rowe
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2012       Impact factor: 1.807

5.  Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice.

Authors:  L Beck; Y Soumounou; J Martel; G Krishnamurthy; C Gauthier; C G Goodyer; H S Tenenhouse
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.

Authors:  Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White
Journal:  JCI Insight       Date:  2019-02-21

7.  Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.

Authors:  Baozhi Yuan; Masanori Takaiwa; Thomas L Clemens; Jian Q Feng; Rajiv Kumar; Peter S Rowe; Yixia Xie; Marc K Drezner
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 8.  The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.

Authors:  Peter S N Rowe
Journal:  Cell Biochem Funct       Date:  2012-05-09       Impact factor: 3.685

Review 9.  Kidney and phosphate metabolism.

Authors:  Nak-Won Choi
Journal:  Electrolyte Blood Press       Date:  2008-12-31

10.  PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism.

Authors:  Lesya V Zelenchuk; Anne-Marie Hedge; Peter S N Rowe
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.